Galectin Therapeutics

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone

Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics' Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy

The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by 35.27%. This is why it happened.

Galectin Therapeutics Stock Price Increased 35.27%: Why It Happened

Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis

Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study

NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2020. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at  www.sec.gov .

Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update

NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, has been invited to make a presentation, entitled “Belapectin, a Galectin-3 Inhibitor in Phase 2b/3 for the Treatment of NASH Cirrhosis,” at the 4th Annual Digital NASH Summit . Dr. Boudes will be speaking at 09:00 AM EST on December 17, 2020.

Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company's Three Active Clinical Trials Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company's Three Active Clinical Trials

Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation

Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated

Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020

Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis

Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today

Investors need to pay close attention to Galectin Therapeutics (GALT) stock based on the movements in the options market lately.

Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options

Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020

NORCROSS, Ga., Sept.  10, 2020  (GLOBE NEWSWIRE) --   Galectin Therapeutics Inc.   (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference, on Monday, September 14, 2020, at 12:30 p.m. EDT.

Galectin Therapeutics Inc. to Present at the H.C.

Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board

Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer

NASH-RX Trial Continues to Enroll New Patients  NASH-RX Trial Continues to Enroll New Patients

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update

Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy

UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis

Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis

As of late, it has definitely been a great time to be an investor in Galectin Therapeutics.

Galectin Therapeutics' Shares March Higher, Can It Continue?

NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update

The first patient currently expected to be enrolled in the second quarter of 2020 The first patient currently expected to be enrolled in the second quarter of 2020

Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis

Ampio Pharmaceuticals Inc

CytoDyn Inc.

Gilead Sciences

Roche Holding AG

Finding The Kink In COVID-19's Armor - Preventing ARDS

NORCROSS, Ga., April  02, 2020  (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.

Galectin Therapeutics Update on the Impact of COVID-19

Galectin Therapeutics: An Even Better Buy As It Hits 52-Week Lows

Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage  of NASH-RX Study

Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis

Lannett Company

Verrica Pharmaceuticals Inc

Zoetis

Small Drug Stock Outlook: Innovation Holds the Key to Growth

Merck

I provide a basic overview of Galectin Therapeutics, and where it, and galectin-3 research, stands today.

News for Galectin Therapeutics Stock (GALT)